济南包茎可上翻(济南生殖器太敏感) (今日更新中)

SAN DIEGO (KGTV) — UC San Diego Health and three other UC Health medical centers will begin to recruit participants for an antiviral drug being tested to treat the novel coronavirus.The medical system will start "phase II" clinical trials for the antiviral drug remdesivir. The drug has "shown activity in animal models and human clinical trials of SARS-CoV, MERS-CoV, Ebola, Marburg and other viruses," according to UCSD Health.RELATED: San Diego hospitals start drives for personal protective equipmentRemdesivir is not currently approved for the treatment of any infection by the FDA, but is currently undergoing trials for treating multiple viruses, including COVID-19.“With this type of adaptive study design, if remdesivir proves to be safe and active, the clinical trial may be rapidly adapted to remove the requirement for a placebo arm and add a treatment arm that includes other promising antiviral or other investigational drug to compare with the activity of remdesivir," said co-principal investigator Constance Benson, professor of medicine at UC San Diego School of Medicine and an infectious disease specialist at UC San Diego Health.RELATED: Nurse urges people to turn over N95 masks to San Diego hospitalsUC San Francisco, UC Irvine Health, and UC Davis Health are also participating in the trials. The trial is projected to run until April 1, 2023 and involve 440 participants. 1404

SAN DIEGO (KGTV) -- San Diegans requested a record number of mail-in ballots for th 2018 general election, 1.2 million to be exact.Now, as tens of thousands arrive at the Registrar's office every day ahead of election day, new technology is helping make sure every ballot is processed and counted."This is our 144 pocket ballot sorter," says Registrar Michael Vu, showing off one of two brand new machines his office bought with this election in mind."After the 2016 election we said the mail ballot population is so great we need to invest in something that's even higher speed," says Vu.The new machine can process up to 44,000 ballots per hour, twice the number of the old machine. It can also sort them by city and council district. That comes in handy with an election as big as this week's."We have 326 contests on ballot, spanning 485 candidates, and 52 measures on there," says Vu.By late Sunday, the Registrar had already received about 500,000 mail-in ballots. That includes several thousand people who voted early in-person. Vu says he expects that nearly 70% of the people who vote in Tuesday's election will have done so through mail-in ballots.He thinks San Diego could get closer to 100% mail-in ballots in the near future."It's becoming ubiquitous," Vu says.Anyone who hasn't turned in their mail-in ballot yet can still do so, either at a drop off location around San Diego or at a polling place on Tuesday.To find a location, go to sdvote.com. 1474

SAN DIEGO (KGTV) — University of San Diego officials say they are investigating white supremacy social media accounts that claim to have ties to the university.In a joint statement from several USD leadership, the school says in the last 24 hours it has been made aware of Instagram accounts that claim to have ties to the school and are used to "post white supremacy propaganda."USD said it is investigating the source of the social media accounts and are making formal requests to Instagram to remove them, with some already taken down.The school slammed the accounts as "abhorrent and hateful" and condemned the posts. USD's full statement follows: 659

SAN DIEGO (KGTV) — With California hospitals dealing with an “extreme” number of patients, many are struggling to find enough staff to run nearly full intensive care units.The state is urgently searching for 3,000 temporary medical workers to meet the demand, with a focus on nurses trained in critical care.“Staffing is our number one challenge,” Governor Gavin Newsom said last week.The state has contracted with two travel nursing agencies to find reinforcements, including San Diego-based Aya Healthcare, the nation’s largest travel nursing company.“California has the most needs in the country right now,” said Aya vice president Sophia Morris. “It’s the number one state that we’re seeing need.”Aya is onboarding new travel nurses as quickly as possible, Morris said, but at the moment they can’t keep up with demand. Right now, about one-third of the requests for travel nurses are going unfilled, said California Health and Human Services Secretary Dr. Mark Ghaly.“We are adding hundreds and hundreds of new clinicians to start, particularly in California, every week,” Morris said. “So it’s coming. I think it just feels like it’s not coming fast enough.”Aya said it is on track to add about 780 more travel nurses in California by mid-January, on top of the 2,676 travel clinicians that are already on assignment in the state.But some experts say it’s a particularly challenging time to find spare nurses with so many regions across the country dealing with surges.On top of that, the number of registered nurses over 60 has dipped in California, according to researchers at UCSF, who found many older nurses stopped working out of concern for their health or the health of their family.California hospitals are confronting the shortage by trying to free up staff any way they can, including postponing certain medical procedures.The state has also temporarily loosened some restrictions. Typically, California requires one nurse for every two ICU patients. Regulators have temporarily relaxed that requirement to one nurse for every three ICU patients.California has also shortened the quarantine period for healthcare staff exposed in certain situations from 10 days to 7.The state has sent more than 600 temporary healthcare workers to hard-hit counties from the National Guard, the California Health Corps and other partnerships, but officials are still looking for more.State officials have even started reaching out to other countries like Australia and Taiwan to get much-needed medical workers. 2520

SAN DIEGO (KGTV) — When you are out in public, it is virtually impossible to tell who has immunity to the coronavirus and who is susceptible.A San Diego-based company is trying to change that by developing two new COVID-19 monitoring systems that are as easy as checking someone’s forearm.Diomics is developing a device that looks like a nicotine patch that the company says can reveal the presence of SARS-CoV-2 antibodies in 24 to 36 hours. The patch is intended to be worn for one to two weeks, offering people a way to monitor -- and potentially display -- their infection status, according to CEO Anthony Zolezzi.When the patch, named Diocheck, detects antibodies circulating in the blood, it turns red.“We think this is an integral piece of getting things back to normal,” Zolezzi said. “This can get the country back operating and get us comfortable that the people around us aren’t infected.”A second device, made from thousands of tiny polymer beads, can be injected into the skin and offer COVID monitoring for six months to a year, Zolezzi said. The company is still testing how long the test can stay active before it’s safely absorbed by the body.The company plans to launch clinical trials at UC Irvine next month.Zolezzi envisions the tests would be useful for employees in numerous sectors, including the airline industry, the cruise industry, the gambling industry and the military, offering a new way to detect and rapidly quarantine infected individuals.Once a coronavirus vaccine is released, the tests could be a useful companion, he said, since it will likely take several weeks to develop protective antibodies after inoculation. An individual wearing the patch, for example, could find out when they have antibodies circulating in the blood.The tests could also show when a person begins to lose antibodies. Studies have show individuals with a mild coronavirus infection lose antibodies after a few months, and it’s common for vaccines to require multiple doses.“This patch will show you, when the color dissipates, it’s because your antibodies have dissipated,” Zolezzi said. “That’s the time when you need to get a boost, or some type of prophylaxis.”The small biotech firm with less than 20 employees is leveraging technology that’s more than 100 years old.In 1907, a French physician named Charles Mantoux developed an injection test for tuberculosis that produces a raised, red dot on the skin when the bacteria is detected. This is the standard test given today.“All we’re doing is modernizing it,” Zolezzi said. The company’s patented slow-release material allows for much longer monitoring, he added.Diomics was making skin care, wound care and diabetes products before the pandemic shifted the company’s focus. Their components are FDA approved individually, but will need new approval for this use, Zolezzi said.Zolezzi said production is underway, but the company is hoping to partner with a large drugmaker to rapidly scale up manufacturing. Their goal is to have products on the market by the end of the year. 3055

来源：资阳报